Press Releases

Oncopeptides Capital Markets Day December 14th in New York

December 13, 2018 - Other press release

Stockholm – December 13, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) will hold its Capital Markets Day in New York tomorrow, Dec 14, between 14:30 – 17:00 CET (8:30-11:00 ET). For those who canno...

Read more

Bulletin from the Extraordinary General Meeting in Oncopeptides AB (PUBL)

December 5, 2018 - Regulatory press release

Stockholm, Sweden –December 5, 2018 – An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held today, at Tändstickspalatset in Stockholm. At the Extraordinary General Meeting, the foll...

Read more

Program for Oncopeptides Capital Markets Day December 14th, 2018

December 5, 2018 - Other press release

Stockholm – December 5, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) have previously announced that they will host a Capital Markets Day in New York. The program is now available below and on the c...

Read more

Interim data from the ongoing HORIZON trial with melflufen presented in an oral presentation at the 60th American Society of Hematology Meeting

December 3, 2018 - Regulatory press release

Stockholm – December 3, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Professor Paul G. Richardson presented updated interim data with melflufen (Ygalo®) from the ongoing HORIZON tria...

Read more

Oncopeptides presents first interim data from the ongoing combination trial ANCHOR with melflufen at the 60th American Society of Hematology Meeting, ASH

December 1, 2018 - Regulatory press release

Stockholm – December 1, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today a presentation of the first interim data with melflufen (Ygalo®) from the ongoing phase I/II study ANCHOR at the ...

Read more

Number of shares and votes in Oncopeptides

November 30, 2018 - Regulatory press release

Stockholm — 30 November, 2018 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the com...

Read more

Additional steps towards the commercialization of Ygalo®

November 5, 2018 - Other press release

Stockholm - 5 November 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the notice for an Extraordinary General Meeting in which the Nomination Committee is proposing one new candidate for...

Read more

Extraordinary General Meeting in Oncopeptides AB (publ)

November 5, 2018 - Regulatory press release

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Extraordinary General Meeting to be held at Tändstickspalatset, Västra T...

Read more

Oncopeptides to present updated data from the two ongoing trials ANCHOR and HORIZON in patients with RRMM at ASH in December 2018

November 1, 2018 - Regulatory press release

Stockholm – 1 November 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the abstracts for the 60th American Society of Hematology (ASH) meeting (December 1st-4th, San Diego, California) hav...

Read more

Number of shares and votes in Oncopeptides

October 31, 2018 - Regulatory press release

Stockholm —October 31, 2018 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the com...

Read more

Interim Report July – September 2018

October 26, 2018 - Regulatory press release

“Broad based progress”

Read more

Oncopeptides to host a Capital Markets Day in New York on December 14th

October 25, 2018 - Other press release

Stockholm – October 25, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will host a Capital Markets Day on December 14th between 8.30-11.00 AM ET in New York.  Speakers will in...

Read more

Nomination Committee appointed in respect of AGM 2019 in Oncopeptides

October 15, 2018 - Other press release

Stockholm - October 15, 2018 - According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on 17 May 2018, the Nomination Committee...

Read more

Oncopeptides to present at the Jefferies London Healthcare Conference on November 14th

October 12, 2018 - Other press release

Stockholm – October 12, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present at Jefferies London Healthcare Conference on November 14th at 3.20 PM local time (GMT), t...

Read more

First patient starts treatment with Ygalo® in Oncopeptides’ Phase II study BRIDGE in RRMM patients with renal impairment

September 18, 2018 - Other press release

Stockholm – 18 September 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the first patient has started treatment in the company's Phase II BRIDGE trial designed to study the Pharmacokinetics (PK...

Read more

Number of shares and votes in Oncopeptides

August 31, 2018 - Regulatory press release

Stockholm —31 August, 2018 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company’s incen...

Read more

Anders Martin-Löf has been appointed as the new CFO of Oncopeptides

August 9, 2018 - Regulatory press release

Stockholm – August 9, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Anders Martin-Löf, has been appointed as the new CFO of Oncopeptides and will join the company in No...

Read more

Number of shares and votes in Oncopeptides

July 31, 2018 - Regulatory press release

Stockholm —31 July, 2018 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company’s incen...

Read more

Interim Report April-June 2018

July 13, 2018 - Regulatory press release

“General knowledge and understanding of Oncopeptides and our clinical strategy has greatly increased during the spring”

Read more

Oncopeptides present updated interim data from the ongoing HORIZON trial with Ygalo® at the 23rd Congress of The European Hematology Association (EHA)

June 15, 2018 - Regulatory press release

Stockholm – June 15, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they are presenting updated interim data with Ygalo® (melflufen) from the ongoing HORIZON trial at the 23rd EH...

Read more

Oncopeptides to present at the Jefferies Healthcare Conference in New York on June 7th

May 29, 2018 - Other press release

Stockholm – May 29, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present at Jefferies annual Healthcare Conference in New York on June 7th at 1.30PM EST, the presentation w...

Read more

Bulletin from the Annual General Meeting in Oncopeptides AB (Publ)

May 17, 2018 - Regulatory press release

Stockholm, Sweden – 17 May 2018 – Oncopeptides AB (publ)’s (ONCO) Annual General Meeting 2018 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the following principal resolu...

Read more

Oncopeptides AB Interim report January – March 2018

May 17, 2018 - Regulatory press release

Stockholm — May 17, 2018 — Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the first quarter 2018 report.

Read more

Oncopeptides has appointed a Clinical Advisory Board consisting of internationally recognized researchers within clinical development in hematology

April 23, 2018 - Other press release

Stockholm – April 23 2018 – Oncopeptides AB (Nasdaq Stockholm, ONCO) today announced that the company has appointed a Clinical Advisory Board. The aim is to identify development opportunities both wit...

Read more

Oncopeptides Annual Report for 2017

April 18, 2018 - Regulatory press release

Stockholm – April 18 2018 – Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the Annual Report for 2017 now is available at the company’s website: www.oncopeptides.com.

Read more

Preparing for commercialisation of Ygalo®

April 18, 2018 - Other press release

Stockholm - 18 April 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) yesterday announced the notice for the AGM in which the Nomination Committee is proposing two new candidates for the Board of Directors....

Read more

ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)

April 17, 2018 - Regulatory press release

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra T...

Read more

First patient starts treatment in Oncopeptides’ Phase I / II ANCHOR study with Ygalo®

April 12, 2018 - Other press release

Stockholm - 12 April 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the first patient has started treatment in the company's Phase I / II ANCHOR trial designed to study Ygalo® in ...

Read more

Number of shares and votes in Oncopeptides

March 29, 2018 - Regulatory press release

Stockholm - March 29, 2018 - Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of the issue of 3,980,000 shares, which...

Read more

Oncopeptides strengthens its management team with Dr Christian Jacques as EVP Clinical Strategy and Chief Scientific Officer

March 26, 2018 - Regulatory press release

Stockholm – March 26th, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that it has broaden its management team with the appointment of Dr Christian Jacques as Executive Vice President C...

Read more

Oncopeptides has completed a directed share issue of approximately SEK 314 million

March 22, 2018 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION...

Read more

Oncopeptides intends to make a directed share issue

March 21, 2018 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION...

Read more

Additional patent protection for Ygalo® granted in Japan until October 2033

March 8, 2018 - Other press release

Stockholm - March 8, 2018 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the Japanese Patent Office (JPO) recently issued a notice that they will grant an additional Japanese patent to...

Read more

Oncopeptides AB Year-end report 2017

February 22, 2018 - Regulatory press release

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the Year-end report 2017. “With increasing clinical data the possible role for Ygalo® in helping patients with myeloma beco...

Read more